Emyria Ltd (ASX:EMD) MD Michael Winlo talks Proactive through the highlights of its June quarter. The company initiated the acquisition of the Pax Centre, extending its reach in the mental health space.
EMD received Human Research Ethics Committee approval to commence EMDMA-001, a novel MDMA-assisted therapy trial for PTSD. Also, at the start of the period, Emyria signed an exclusive licensing and commercialisation term sheet with Aspen Pharmacare Australia, securing a major partner to support the registration and commercialisation of the prospective EMD-RX5 treatment for mild anxiety and stress.
Winlo said in the companys quarterly statement: Emyrias acquisition of The Pax Centre this quarter is a substantial extension of our capabilities and expertise in mental health.
By integrating the Pax Centre with Emerald Clinics we aim to create a thriving, multidisciplinary clinical service that generates growing revenues while capturing robust clinical data to support our ongoing cannabinoid and MDMA-inspired medicine development programs.
We believe the unique wraparound care model we are building offers advantages over alternative models for delivering promising emerging interventions like MDMA and psilocybin-assisted therapy and that the data we are gathering can help advance the development and registration of treatments with potential to help large patient populations.
+61 413 713 744
View source version on newsdirect.com: https://newsdirect.com/news/emyria-advances-development-and-commercialisation-of-unique-drug-products-938739456